Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» September 2010
September 2010
Vivus Races to Capture U.S. Approval of Obesity Drug
Vivus Races to Capture U.S. Approval of Obesity Drug
Seeking Alpha
obesity
Vivus
Qnexa
Orexigen
Contrave
Arena Pharmaceuticals
Theravance in Neutral Lane
Theravance in Neutral Lane
Yahoo/Zacks.com
Theravance
Vibativ
GSK
AstraZeneca Prostate Cancer Drug Fails
AstraZeneca Prostate Cancer Drug Fails
TheStreet.com
prostate cancer
AstraZeneca
zibotentan
Dendreon
Provenge
Another Setback for Roche's Cancer Drug
Another Setback for Roche's Cancer Drug
Seeking Alpha
Roche
Avastin
colon cancer
Private Biotechs Take Different Avenues to Rake in Cash
Private Biotechs Take Different Avenues to Rake in Cash
Seeking Alpha
Reata
Abbott Laboratories
Bardoxolone
chronic kidney disease
Asthmatx
Boston Scientific
CytomX
Emergent BioSolutions
GSK's Diabetes Pill: Lessons Learned, Unanswered Questions
GSK's Diabetes Pill: Lessons Learned, Unanswered Questions
Seeking Alpha
GSK
Avandia
diabetes
$93,000 cancer drug: How much is a life worth?
$93,000 cancer drug: How much is a life worth?
Yahoo/AP
Provenge
Dendreon
Revlimid
Celgene
A Busy Week for Multiple Sclerosis News
A Busy Week for Multiple Sclerosis News
Seeking Alpha
Novartis
Merck KGaA
Gilenya
multiple sclerosis
cladribine
Biogen Idec
Bayer
Teva Pharmaceuticals
Will the FDA Give Vivus More Time Before the Final Judgment on Qnexa?
Will the FDA Give Vivus More Time Before the Final Judgment on Qnexa?
Seeking Alpha
Qnexa
Vivus
obesity
Diabetes Therapeutic Market Reached $24.9 Billion in 2009
Diabetes Therapeutic Market Reached $24.9 Billion in 2009
PR-USA.net
diabetes
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »